Indicationverzenio is indicated for the treatment of hormone receptor-positive (hr+), human epidermal growth factor receptor 2-negative (her2-) advanced or metastatic breast cancer (mbc):**in combination with fulvestrant for women with disease progression following endocrine therapy.**in combination with an aromatase inhibitor (ai) for postmenopausal women as initial endocrine-based therapyas a single agent for adult patients with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.